Aspire Biopharma Holdings (ASBP) Change in Accured Expenses (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has 5 years of Change in Accured Expenses data on file, last reported at -$316955.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 185.48% year-over-year to -$316955.0 in Q1 2026; TTM through Mar 2026 was $841159.0, a 1429.9% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 19.18% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$316955.0, down from $1.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for ASBP reached as high as $1.2 million in Q4 2025 and fell as low as -$316955.0 in Q1 2026.
• Historically, Change in Accured Expenses has averaged $63629.8 across 5 years, with a median of $12239.0 in 2022.
• Across the five-year window, Change in Accured Expenses sank 257.73% in 2023 and soared 822.18% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $84618.0 in 2022, then plunged by 43.72% to $47626.0 in 2023, then plunged by 546.93% to -$212855.0 in 2024, then soared by 644.09% to $1.2 million in 2025, then plunged by 127.37% to -$316955.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$316955.0 in Q1 2026, $1.2 million in Q4 2025, and -$111026.0 in Q1 2025.